Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BANNER: GSK3810109A in HIV-1
NCT04871113Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Jun 2021
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Anti-infectious Disease mAbs
- Countries
- 6
01
Overview
A Phase 2 trial of VH3810109 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Jun 2021; status: completed.
02
Drugs
VH3810109
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04871113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871113.